Healthcare Analysts discuss Non-muscle invasive bladder cancer (NMIBC) (relevant companies CG Oncology (CGON) and Protara Therapeutics (TARA) on an Analyst/Industry conference call to be held on April 9 at 1 pm. Webcast Link
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology price target raised to $100 from $80 at H.C. Wainwright
- CG Oncology price target raised to $90 from $60 at UBS
- Cretostimogene’s PIVOT‑6 Upside: Anticipated Superiority in Recurrence‑Free Survival Supports Buy on CG Oncology
- CG Oncology price target raised to $72 from $65 at BofA
- Buy Rating on CG Oncology Driven by PIVOT-006 Differentiation and 2026 Clinical, Regulatory Catalysts Supporting Favorable Risk–Reward